Phase 1 Alzheimer's Disease Trial, Recruiting NCT07169630 Sponsor: National Institute of Mental Health (NIMH) Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 1 Alzheimer's Disease Trial, Recruiting

NCT07169630
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have been diagnosed with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI):

  • You are 50 years of age or older
  • You are able to understand the study and sign a consent form, or have a legal representative who can do this on your behalf
  • A neurologist or psychiatrist has diagnosed you with MCI or Alzheimer's disease
  • You are in good general health, based on your medical history and a physical exam
  • A check of the pulse in your wrist has confirmed good blood flow and that there are no metal objects in either wrist
  • You are willing to follow certain lifestyle guidelines set by the study

If you are a healthy volunteer:

  • You are 50 years of age or older
  • You are able to understand the study and sign a consent form yourself
  • You are in good general health, based on your medical history and a physical exam, and have no memory or thinking problems
  • A check of the pulse in your wrist has confirmed good blood flow and that there are no metal objects in either wrist
  • You are willing to follow certain lifestyle guidelines set by the study

Who may not be able to join:

  • You have significant abnormal results on a heart tracing (EKG) or blood tests
  • You have taken anti-inflammatory medications (such as ibuprofen or naproxen) in the two weeks before the brain scan, or have taken aspirin, steroid medications (other than skin creams), or immune-suppressing drugs in the past month
  • You have another major brain or medical condition that affects memory or thinking, such as a brain structural problem, metabolic disease, or infection
  • You have an unstable health condition — such as an active infection or untreated cancer — that the research team feels makes it unsafe for you to participate
  • You are unable to travel to the NIH (National Institutes of Health)
  • You have recently had radiation exposure through other research studies that, combined with this study, would exceed safe limits
  • You are unable to lie flat and still for at least two hours (for example, due to claustrophobia, body weight exceeding the scanner's limit, or uncontrollable behavioral symptoms)
  • You have a current problem with substance use or alcohol use disorder
  • You are currently being treated with, or have previously been treated with, an amyloid-targeting antibody medication such as lecanemab
  • You are unable to have an MRI scan — for example, because you have a pacemaker, brain stimulator, certain dental implants, metal clips in blood vessels, metal prostheses, cochlear implants, permanent eyeliner, implanted drug pumps, or metal fragments in the eye
  • You are currently pregnant or breastfeeding
  • You have HIV infection
  • You do not speak English (because the memory and thinking tests used in this study have only been validated in English)
  • You are under 18 years of age

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Paul A Parcon, M.D., National Institute of Mental Health (NIMH)

Phone: (301) 827-6599

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
14 July 2026
Est. completion
11 April 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine whether PDE4B radioligand binding is increased in medial temporal lobe of participants with AD or MCI (both A <= positive) compared to age-and sex matched HVs (who are A <= negative.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov